OCULAR THERAPEUTIX, INC Cash and Cash Equivalents, Period Increase (Decrease)
OCULAR THERAPEUTIX, INC (OCUL) reported Cash and Cash Equivalents, Period Increase (Decrease) of $8.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$9.63M.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$11.88M, a 392.42% decline year-over-year.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $8.37M, a 327.32% increase year-over-year.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $21.75M, a 40.95% increase year-over-year.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was $8.60M, a 299.72% increase from fiscal 2016.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $2.15M.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$6.61M, a 133.23% decline from fiscal 2014.
- OCULAR THERAPEUTIX, INC cash and cash equivalents, period increase (decrease) for fiscal 2014 was $19.89M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$21.51M derived: sum of 2 quarters · filed 2018-03-08 | -$13.14M derived: sum of 3 quarters · filed 2018-03-08 | $8.60M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$11.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$3.52M derived: sum of 2 quarters · filed 2017-11-07 | $18.23M 10-Q · filed 2017-11-07 | -$1.07M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $8.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $30.11M 10-Q · filed 2017-08-08 | $10.81M derived: sum of 3 quarters · filed 2018-03-08 | $14.88M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $21.75M 10-Q · filed 2017-05-05 | $2.45M derived: sum of 2 quarters · filed 2018-03-08 | $6.51M derived: sum of 3 quarters · filed 2018-03-08 | $8.47M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | -$19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$15.23M derived: sum of 2 quarters · filed 2018-03-08 | -$13.28M derived: sum of 3 quarters · filed 2018-03-08 | $2.15M 10-K · filed 2018-03-08 |
| 2016-09-30 | $4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.02M derived: sum of 2 quarters · filed 2017-11-07 | $21.45M 10-Q · filed 2017-11-07 | $11.04M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $17.39M 10-Q · filed 2017-08-08 | $6.97M derived: sum of 3 quarters · filed 2018-03-08 | -$30.52M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $15.43M 10-Q · filed 2017-05-05 | $5.01M derived: sum of 2 quarters · filed 2018-03-08 | -$32.47M derived: sum of 3 quarters · filed 2018-03-08 | $33.69M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$47.90M derived: sum of 2 quarters · filed 2018-03-08 | $18.26M derived: sum of 3 quarters · filed 2018-03-08 | -$6.61M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$37.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $28.68M derived: sum of 2 quarters · filed 2016-11-09 | $3.81M 10-Q · filed 2016-11-09 | -$39.69M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $66.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $41.29M 10-Q · filed 2016-08-09 | -$2.21M derived: sum of 3 quarters · filed 2017-03-10 | $58.74M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$24.87M 10-Q · filed 2016-05-10 | -$68.37M derived: sum of 2 quarters · filed 2017-03-10 | -$7.42M derived: sum of 3 quarters · filed 2017-03-10 | -$227.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$43.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $17.45M derived: sum of 2 quarters · filed 2017-03-10 | $24.64M derived: sum of 3 quarters · filed 2017-03-10 | $19.89M 10-K · filed 2017-03-10 |
| 2014-09-30 | $60.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $68.14M derived: sum of 2 quarters · filed 2015-11-10 | $63.39M 10-Q · filed 2015-11-10 | $59.27M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $7.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $2.44M 10-Q · filed 2015-08-10 | -$1.67M derived: sum of 3 quarters · filed 2016-03-10 | -$5.09M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | -$4.75M 10-Q · filed 2015-05-15 | -$8.87M derived: sum of 2 quarters · filed 2016-03-10 | -$12.28M derived: sum of 3 quarters · filed 2016-03-10 | |
| 2013-12-31 | -$4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$7.53M derived: sum of 2 quarters · filed 2016-03-10 | -$6.35M 10-K · filed 2016-03-10 | |
| 2013-09-30 | -$3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$2.24M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $1.18M 10-Q · filed 2014-08-29 | |||
| 2012-12-31 | $18.52M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |